For research use only.
| Verified Samples | Verified Samples in WB: Rat heart, Mouse heart, Hela Verified Samples in IHC: Human colon carcinoma, Mouse brain |
| Dilution | WB 1:1000-2000, IHC 1:100-200 |
| Isotype | IgG |
| Host | Mouse |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IHC-p |
| Clonality | Monoclonal |
| Immunogen | Recombinant Protein |
| Abbre | STAT3 |
| Synonyms | 1110034C02Rik, ADMIO, APRF, AW109958, Acute Phase Response Factor, Acute-phase response factor, DNA binding protein APRF, FLJ20882, HIES, MGC16063, Signal transducer and activator of t, Signal transducer and activator of transcription 3 (acute phase response factor) |
| Swissprot | |
| Observed MW | 79 ,86kDa The actual band is not consistent with the expectation. Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cytoplasm. Nucleus. Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1. |
| Tissue Specificity | Heart, Brain, Placenta, Lung, Liver, Skeletal muscle, Kidney and pancreas |
| Concentration | 1 mg/mL |
| Buffer | Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer, 0.5% protein protectant and 50% glycerol. |
| Purification Method | Protein A purification |
| Research Areas | Cancer, Cardiovascular, Epigenetics and Nuclear Signaling, Developmental Biology, Signal Transduction, Stem Cells |
| Clone No. | 3F4 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
| background | Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:17344214). |
Other Clones
1 Results
Other Formats
1 Results
Unconjugated
